Follow
Elena Nicod
Elena Nicod
Verified email at lse.ac.uk
Title
Cited by
Cited by
Year
Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy
TL Jackson, E Nicod, A Angelis, F Grimaccia, AT Prevost, ARH Simpson, ...
Retina 33 (10), 2012-2017, 2013
1282013
Symptomatic vitreomacular adhesion
TL Jackson, E Nicod, A Simpson, A Angelis, F Grimaccia, P Kanavos
Retina 33 (8), 1503-1511, 2013
1192013
Differences in costs of and access to pharmaceutical products in the EU
P Kanavos, S Vandoros, R Irwin, E Nicod, M Casson
EPRS: European Parliamentary Research Service, 2011
1192011
Recommendations from the European working Group for Value Assessment and Funding Processes in rare diseases (ORPH-VAL)
L Annemans, S Aymé, Y Le Cam, K Facey, P Gunther, E Nicod, M Reni, ...
Orphanet journal of rare diseases 12, 1-15, 2017
992017
Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions
E Nicod, P Kanavos
Health Policy 108 (2-3), 167-177, 2012
982012
Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a systematic review and metaanalysis
TL Jackson, E Nicod, A Angelis, F Grimaccia, AT Prevost, ARH Simpson, ...
Retina 33 (6), 1099-1108, 2013
972013
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug …
E Nicod
The European Journal of Health Economics 18, 715-730, 2017
832017
Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature
TL Jackson, E Nicod, A Angelis, F Grimaccia, E Pringle, P Kanavos
Retina 37 (5), 886-895, 2017
822017
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom
A Angelis, P Kanavos, J López-Bastida, R Linertová, E Nicod, ...
BMC health services research 15, 1-8, 2015
722015
HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries
E Nicod, L Annemans, A Bucsics, A Lee, S Upadhyaya, K Facey
Health Policy 123 (2), 140-151, 2019
682019
The impact of health technology assessments: an international comparison
P Kanavos, E Nicod, S Van Den Aardweg, S Pomedli
EURO OBSERVER-HEALTH POLICY BULLETIN OF THE EUROPEAN OBSERVATORY ON HEALTH …, 2010
582010
Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: a mixed methods study
E Nicod, P Kanavos
Health Policy 120 (1), 35-45, 2016
542016
What is wrong with orphan drug policies? Suggestions for ways forward
P Kanavos, E Nicod
Value in health 15 (8), 1182-1184, 2012
522012
Scientific and social value judgments for orphan drugs in health technology assessment
E Nicod, P Kanavos
International Journal of Technology Assessment in Health Care 32 (4), 218-232, 2016
432016
Short-and long-term effects of value-based pricing vs. external price referencing
P Kanavos, E Nicod, J Espin, S Van Den Aardweg
Eminet, LSE, 2010
422010
The use of patient-reported outcome measures in rare diseases and implications for health technology assessment
A Whittal, M Meregaglia, E Nicod
The Patient-Patient-Centered Outcomes Research 14, 485-503, 2021
352021
Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches
E Nicod, A Whittal, M Drummond, K Facey
Orphanet journal of rare diseases 15, 1-14, 2020
342020
Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer
O Ciani, M Cucciniello, F Petracca, G Apolone, G Merlini, S Novello, ...
BMJ open 9 (2), e025483, 2019
342019
Dealing with uncertainty and accounting for social value judgments in assessments of orphan drugs: evidence from four European countries
E Nicod, KB Brigham, I Durand-Zaleski, P Kanavos
Value in Health 20 (7), 919-926, 2017
332017
Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel
KM Facey, J Espin, E Kent, A Link, E Nicod, A O’Leary, E Xoxi, ...
Pharmacoeconomics 39, 1021-1044, 2021
302021
The system can't perform the operation now. Try again later.
Articles 1–20